Saladax Biomedical, Inc. Completes $9 Million Debt Financing With ... ( BETHLEHEM Pa. June 21 2011 /- Saladax...)

Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital

Date:6/21/2011

BETHLEHEM, Pa., June 21, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the completion of a $9 million debt financing with GE Capital.

The secured term loan facility will be used for commercialization of the company's My5-FU™ assay, the first of Saladax's innovative dose management tests commercially available in the European Union (EU) and Australia as a convenient diagnostic kit that measures levels of 5-flourouracil, a widely used chemotherapy drug administered in conjunction with other drugs in therapy for colorectal cancer and other solid tumors. The funds will also be used for further development of the company's additional assays.

"We are pleased to welcome GE Capital as an investor in the company," said Edward L. Erickson, president and CEO of Saladax. "This loan facility will enable Saladax to continue developing and commercializing novel diagnostic products to achieve the promise of personalized medicine today."

Peter Gibson, vice president at GE Capital, Healthcare Financial Services – Life Science Finance, said, "Given that drug optimization through dose management has not been prevalent in oncology, we're delighted to invest in Saladax as the company has already achieved tangible results in this area. We look forward to working with the Saladax as it continues expanding into additional markets worldwide."

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response an
'/>"/>

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
2. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
3. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
4. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
5. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome

Post Your Comments:

(Date:5/22/2013)... 22, 2013 STEPh, Inc., a full service ... of their web site ( http://www.stephreports.com ) ... About STEPh Reports STEPh Reports are ... Each STEPh Report assesses the competitive landscape by ... year, company, and specific key issues. STEPh Reports are ...

(Date:5/22/2013)... May 22, 2013 Upsher-Smith Laboratories, ... of its global Phase III clinical trial ... program for the management of epilepsy in ... USL255 is specifically engineered to provide convenient ... blood levels observed with currently available treatment ...

(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter. The Facebook homepage ... Says CEO Bruce J. ...

Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4 Medifirst Solutions, Inc. Announces Update To Shareholders 2

[0] Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site [0] Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures [0] Medifirst Solutions, Inc. Announces Update To Shareholders

... CARSON CITY, Nev., Dec. 21, 2011 Denali Concrete ... has commenced patient enrollment for a phase 3 clinical ... administered orally, in patients with moderate-to-severe Dry Eye Syndrome. ... States, Europe and Israel. The randomized, double-masked clinical trial ...

... and BEDMINSTER, N.J., Dec. 20, 2011 QRxPharma Limited (ASX: QRX ... of Intent (LOI) with Actavis Inc. for the formation of ... acute pain marketplace. MoxDuo IR is a patented ... Inc. is a subsidiary of Actavis Group, hf a privately ...

Cached Medicine Technology:Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study 2 QRxPharma Announces Strategic Partnership with Actavis 2 QRxPharma Announces Strategic Partnership with Actavis 3 QRxPharma Announces Strategic Partnership with Actavis 4 QRxPharma Announces Strategic Partnership with Actavis 5

Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study QRxPharma Announces Strategic Partnership with Actavis

(Date:5/22/2013)... SAN FRANCISCO Researchers in genomic health disparities from ... the Stanford University School of Medicine have teamed up ... Conference to Eliminate Health Disparities in Genomic Medicine." ... role of nonprofits, business and government to reduce these ... of the United States, individuals within underserved groups continue ...

(Date:5/22/2013)... , , WEDNESDAY, May 22 (HealthDay News) -- Migraines and ... but new research indicates the combination of the two ... smaller brain. , , Already aware that people with ... to determine if having both conditions together affected total ... percent -- isn,t alarming, study authors said, but needs ...

(Date:5/22/2013)... York, US (PRWEB) May 22, 2013 ... Awards , Read the press release here: http://bit.ly/13DkFfk ... Merrill DataSite® was named “Information Management Product/Service of the ... held in March at The Colony Hotel in Palm ... secure virtual data room (VDR) solution that ...

(Date:5/22/2013)... Recent tragedies including the Oklahoma tornado, ... in Newtown, Connecticut all resulted in serious, and ... medical practitioners train to respond to both adult ... for Children (EMSC) Program specifically provides instruction, education ... patients. It is estimated 30 million children will ...

(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science ... sharing a recipe for making energy bars at home. , ... ,” takes a recipe modified from one recently featured ... day it gets more and more difficult to understand what ... size of the nutrition label continues to grow and consumers ...

Breaking Medicine News(10 mins):Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 3 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3 Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2 Health News:How To "Make Your Own Healthy Energy Bars" 2

[0] Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine [0] Having Both Migraines, Depression May Mean Smaller Brain [0] Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year”[0] When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care [0] How To "Make Your Own Healthy Energy Bars"

... NEW YORK, Sept. 3 As millions of teens head back ... , , Teens are at a greater risk of ... largely to lack of experience. Many of those crashes could be avoided ... group that produces free driver education programs. , , ...

... This release is available in German . ... weeks before surgery can halve their risk of poor wound ... Efficiency in Health Care (IQWiG) concludes in information published on ... of stress is not easy "It is not easy ...

... 3, 2009) National Cancer Institute (NCI) has renewed ... grant in prevention, diagnosis and treatment of ovarian cancer, ... and the University of Pennsylvania. First approved in ... Fox Chase-Penn Ovarian SPORE. "The SPORE program has always ...

... , , , NEW YORK, Sept. ... in its catalogue. , , U.S. Markets ... http://www.reportlinker.com/p0109210/US-Markets-for-Addiction-and-Substance-Abuse-Treatment.html , , ... , This BCC Research report details the complicated world ...

... , NEW YORK, Sept. 3 , , ... catalogue. , , Healthcare Information Technology ... This Report: , , , ... care IT technologies , Forecasts trends and sales ...

... , , , LANSING, Mich., ... Michigan is launching a television awareness campaign this holiday weekend ... , "Mental illness can be treated and most ... the support of their family and friends," said Sherri Solomon, Executive ...

Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation It pays to quit smoking before surgery NCI renews Fox Chase / Penn Ovarian Cancer 'SPORE' grant for a third 5-year term Reportlinker Adds U.S. Markets for Addiction and Substance Abuse Treatment Report Reportlinker Adds Healthcare Information Technology Report National Alliance on Mental Illness (NAMI Michigan) Launches TV Awareness Campaign

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Promazine, Urine Prolactin Macroadenoma Prograf Proloprim